Högskolan i Skövde

his.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • apa-cv
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Transcriptome analysis of the sumo cycle enzymes in rhabdomyosarcoma cells: Rhabdomyosacroma and SUMO network
University of Skövde, School of Health Sciences.
2020 (English)Independent thesis Basic level (degree of Bachelor), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

The Small Ubiquitin-like Modifier (SUMO) moiety is a member of the superfamily of ubiquitin-like proteins (UbLs) including Ubiquitin, Nedd8, FAT10, ISG15 and ATGs. Several proteins are attached by the UbLs through a fine and tuned enzymatic cascade called post-translational modifications (PTM). SUMOylation is the drug-targetable PTM regulated by SUMO and its specific conjugating E1, E2, E3 and deconjugating SENPs enzymes. This PTM regulates several cellular functions, such as cell growth, gene regulation and apoptosis, while deregulation of SUMOylation reaction has been related to promote tumorigenic features. The correlation between different cancer subtypes and SUMO network has previously been described, but this has not been investigated in Rhabdomyosarcoma (RMS) tumor. Rhabdomyosarcoma is a heterogeneous group of malignancies and is derived from primitive myogenic precursors. The most common RMS subtypes are embryonal (ERMS) and alveolar (ARMS). The aim of this project was to investigate whether the SUMO PTM is altered in RMS disease and identify if the deregulation can also contribute to the progression, invasion and radioresistance of RMS tumors. We produced the complete SUMO transcriptome of six different Rhabdomyosarcoma cell lines and validated some targets with specific antibodies. Interestingly, rearrangement of the expression of the SUMO enzymes was discovered among the RMS cells. This evidence suggests that SUMO has the potential to be the next cellular network to study in RMS cells. In the future, the aim is to identify potential SUMO RMS network biomarkers that describe the pathology of the disease and adopt commercial and new drugs to interfere with the deregulated SUMO network by reducing or blocking the metastasis features of RMS.

Place, publisher, year, edition, pages
2020. , p. 28
National Category
Biomedical Laboratory Science/Technology
Identifiers
URN: urn:nbn:se:his:diva-18586OAI: oai:DiVA.org:his-18586DiVA, id: diva2:1445384
External cooperation
Karolinska Institutet
Subject / course
Biomedicine/Medical Science
Educational program
Biomedicine - Study Programme
Supervisors
Examiners
Available from: 2020-06-23 Created: 2020-06-23 Last updated: 2020-06-23Bibliographically approved

Open Access in DiVA

fulltext(2123 kB)195 downloads
File information
File name FULLTEXT01.pdfFile size 2123 kBChecksum SHA-512
e197aa8e9bb32d79f158d70706c347ff2c4f93a08227e6ee99011b1e2f01f60116f5a890b893d313a0c4904c6b31fa115954b13cc9af64284493714c742bde95
Type fulltextMimetype application/pdf

By organisation
School of Health Sciences
Biomedical Laboratory Science/Technology

Search outside of DiVA

GoogleGoogle Scholar
Total: 195 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 458 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • apa-cv
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf